Table 6. Cerebral palsy (as defined by trialists)* (all trials).
| Trial | MgSO4 | Control | Relative risk | 95% confidence interval |
|---|---|---|---|---|
| ACTOMgSO4 [9] | 36/533 (6.8%) | 42/513 (8.2%) | 0.83 | 0.54–1.28 |
| PREMAG [10] | 22/313 (7.0%) | 30/293 (10.2%) | 0.68 | 0.40–1.17 |
| MAGNET [11] | 3/60 (5.0%) | 3/62 (4.8%) | 1.03 | 0.22–4.94 |
| MAGPIE [12] | 2/236 (0.8%) | 5/255 (2.0%) | 0.43 | 0.08–2.21 |
| BEAM [13] | 43/1,133 (3.8%) | 77/1,203 (6.4%) | 0.59 | 0.41–0.86 |
| Overall† | 106/2,275 (4.7%) | 157/2,326 (6.7%) | 0.68 | 0.54–0.87 |
Abbreviations: ACTOMgSO4, Australasian Collaborative Trial of Magnesium Sulphate; BEAM, Beneficial Effects of Antenatal Magnesium Sulfate; MAGNET, Magnesium and Neurologic Endpoints Trial; MAGPIE, MAGnesium sulphate for Prevention of Eclampsia MgSO4, magnesium sulphate; PREMAG, PREterm brain protection by MAGnesium sulphate.
*Available data (participants were included if the cerebral palsy [CP] outcome was known).
†p-value for heterogeneity = 0.74 (the heterogeneity p-value for 1-stage analyses is from Wald chi-square tests for the interaction between treatment and trial in a generalising estimating equation [GEE] model).